Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CVAC 
CureVac NV (CVAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CVAC (4-star) is a REGULAR-BUY. BUY since 86 days. Profits (54.76%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.36
1 Year Target Price $5.36
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 84.68% | Avg. Invested days 49 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.21B USD | Price to earnings Ratio 5.37 | 1Y Target Price 5.36 |
Price to earnings Ratio 5.37 | 1Y Target Price 5.36 | ||
Volume (30-day avg) 6 | Beta 2.53 | 52 Weeks Range 2.37 - 5.72 | Updated Date 08/29/2025 |
52 Weeks Range 2.37 - 5.72 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-15 | When - | Estimate -0.0459 | Actual -0.15 |
Profitability
Profit Margin 37.93% | Operating Margin (TTM) -4959.44% |
Management Effectiveness
Return on Assets (TTM) 23.77% | Return on Equity (TTM) 40.22% |
Valuation
Trailing PE 5.37 | Forward PE 5.24 | Enterprise Value 792707707 | Price to Sales(TTM) 2.37 |
Enterprise Value 792707707 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 1.33 | Enterprise Value to EBITDA 2.85 | Shares Outstanding 225172992 | Shares Floating 125869315 |
Shares Outstanding 225172992 | Shares Floating 125869315 | ||
Percent Insiders 57.37 | Percent Institutions 6.51 |
Upturn AI SWOT
CureVac NV
Company Overview
History and Background
CureVac NV, founded in 2000, pioneers mRNA-based therapies. Initially focused on cancer vaccines, it has expanded into infectious disease vaccines and protein therapies. Significant milestones include developing proprietary mRNA technology and strategic partnerships with pharmaceutical companies.
Core Business Areas
- mRNA-Based Vaccines: Development and commercialization of prophylactic vaccines against infectious diseases, including COVID-19 and influenza.
- mRNA-Based Immunotherapies: Development of cancer immunotherapies using mRNA to stimulate the immune system to attack cancer cells.
- Protein Therapies: Using mRNA technology to produce therapeutic proteins within the patient's body.
Leadership and Structure
The company is led by a management team with experience in biotechnology and pharmaceuticals. It operates with a functional organizational structure, with departments dedicated to research, development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- COVID-19 Vaccine (CVnCoV): CureVac's first-generation COVID-19 vaccine candidate. Trials showed lower efficacy than mRNA vaccines from Pfizer/BioNTech and Moderna. Competitors: PFE, BNTX, MRNA. Revenue from CVnCoV has been significantly lower than projected.
- Second-Generation COVID-19 Vaccine (CV2CoV): Developed in partnership with GSK. This vaccine aims to improve efficacy and thermostability. Competitors: PFE, BNTX, MRNA. Market share data is not yet available as it is still in development. It is not launched commercially.
- Cancer Immunotherapy Programs: Early-stage clinical trials for mRNA-based cancer immunotherapies. Competitors: MRNA, BNTX, small biotechs with cancer immunotherapy candidates.
Market Dynamics
Industry Overview
The mRNA therapeutics market is experiencing rapid growth driven by the success of mRNA-based COVID-19 vaccines. It is highly competitive, with established pharmaceutical companies and emerging biotech firms vying for market share.
Positioning
CureVac is positioned as a pioneer in mRNA technology but faces significant competition from larger companies with more advanced development pipelines and greater resources. It's a niche player trying to improve on 1st generation mRNA.
Total Addressable Market (TAM)
The mRNA therapeutics market is estimated to reach hundreds of billions of dollars in the coming years. CureVac's success depends on developing differentiated products and securing strategic partnerships. In the oncology space alone, the TAM is huge.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology
- Experienced management team
- Established partnerships with GSK and other pharmaceutical companies
- Proprietary mRNA platform
- Early mover in mRNA based therapies
Weaknesses
- Lower efficacy of first-generation COVID-19 vaccine
- Smaller financial resources compared to competitors
- Limited commercialization experience
- Late to the COVID-19 vaccine market
- Significant cash burn
Opportunities
- Development of differentiated mRNA vaccines and therapies
- Expansion of partnerships with pharmaceutical companies
- Advancement of cancer immunotherapy programs
- Expanding to new therapeutic areas using mRNA
- Leveraging its mRNA technology platform for new applications.
Threats
- Intense competition from established pharmaceutical companies
- Regulatory hurdles for mRNA therapies
- Patent disputes
- Clinical trial failures
- Emergence of new technologies that compete with mRNA
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- BNTX
Competitive Landscape
CureVac faces intense competition from larger companies with more established mRNA platforms. Its success depends on developing differentiated products and securing strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by R&D investments and the development of its mRNA platform.
Future Projections: Future growth depends on the successful development and commercialization of its pipeline products, particularly its second-generation COVID-19 vaccine and cancer immunotherapy programs. Analyst estimations can be found on financial platforms.
Recent Initiatives: Recent initiatives include the partnership with GSK for COVID-19 vaccine development and the expansion of its cancer immunotherapy pipeline.
Summary
CureVac is a pioneering mRNA company facing significant headwinds. While its early-stage cancer immunotherapy programs offer potential, it lags behind competitors in the COVID-19 vaccine market. The company needs to demonstrate clinical efficacy and secure additional funding to remain competitive. Its partnership with GSK is critical for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share and other data are estimates and may vary. Investment decisions should be made based on individual risk tolerance and research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CureVac NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-08-14 | CEO, MD & Member of Management Board Dr. Alexander Zehnder M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 825 | Website https://www.curevac.com |
Full time employees 825 | Website https://www.curevac.com | ||
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.